Pharmaceutical

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. As quoted in the press release: Type 1 diabetes currently affects approximately 30 million …

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint.

As quoted in the press release:

Type 1 diabetes currently affects approximately 30 million adults worldwide.1 It is an autoimmune disease in which the body does not produce sufficient amounts of insulin and therefore requires life-long daily insulin administration to regulate blood sugar. For some people with type 1 diabetes, it may be challenging to manage blood sugar levels with insulin alone. People with type 1 diabetes also face risks of complications such as sight loss, heart disease, kidney disease and amputations.

“Despite recent advances in insulin therapy and patient care, optimal glucose control is difficult to achieve in people with type 1 diabetes. Empagliflozin is an effective and well-established medicine used to treat adults with type 2 diabetes, and our comprehensive clinical trial programme continues to investigate the potential benefits it may offer to a range of adults with diabetes”, said Dr. Jyothis George, Global Head of Clinical Development, Therapeutic Area CardioMetabolism, Boehringer Ingelheim. “Boehringer Ingelheim and Lilly look forward to sharing the results of the EASE phase III programme at EASD.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20083.22-538.17
TSXV811.00-45.62
DOW33545.73-719.64
S&P 5004281.52-116.42
NASD13343.68-425.24
ASX7175.80-166.60

COMMODITIES

Commodities
Gold1833.74-0.45
Silver23.65-0.62
Copper4.41-0.11
Palladium2148.00+51.00
Platinum1018.00-12.00
Oil82.57-2.57
Heating Oil2.58-0.06
Natural Gas4.01+0.01

DOWNLOAD FREE REPORTS

×